Palatin Loses Sexual (Dysfunction) Partner
This article was originally published in Scrip
You may also be interested in...
Palatin plans to file the drug for FDA approval in the second half of 2017, but a change in the co-primary endpoint presents a complication.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.